Talazoparib

Talazoparib (trade name Talzenna) is an orally available poly ADP ribose polymerase (PARP) inhibitor developed by Pfizer for the treatment of advanced breast cancer with germline BRCA mutations. Talazoparib is similar to the first in class PARP inhibitor, olaparib. It was approved in 2018 in the United States and 2019 in Europe for germline BRCA-mutated, HER2-negative locally advanced or metastatic breast cancer.